Exceptional Responders With Pancreatic Cancer to Chemotherapy
Exceptional Responders With Pancreatic Cancer to Chemotherapy
This is an observational study enrolling patients with pancreatic cancer to identify genomic
 expression differences between exceptional responders and non-responders to standard of care
 chemotherapy. Data analysis of the gene expression profile of the exceptional responders
 compared to non-responders will define genomic patterns that may help understand their
 response to chemotherapy.
This is an observational study of patients with pancreatic cancer to identify genomic
 expression differences obtained from their circulating tumor cells between exceptional
 responders and non-responders to standard of care chemotherapy. This study requires a 10 mL
 heparinized peripheral blood sample from each study participant at the time of enrollment to
 isolate, enrich and profile circulating tumor cells. Data analysis of the gene expression
 profile will define genomic patterns using Nearest Template Prediction for a predetermined
 panel of therapeutic agents based on standard of care. Chemotherapy selection is
 physician-choice. Information regarding disease progression will be gathered. Data analysis
 will be performed in study participants in the setting of ongoing disease progression.
Inclusion Criteria:

 -  Histological or cytological confirmation of pancreatic adenocarcinoma.

 -  Patient is treatment-naïve or currently receiving chemotherapy.

 -  ECOG performance status 0-2.

 -  Patients must have a hemoglobin of 7.5 g/dl or greater and be hemodynamically stable
 and/or physiologically compensated for their anemia.

 Exclusion Criteria:

 -  HIV positive on antiretroviral therapy

 -  Pregnant or lactating

 -  Prior organ allograft

 -  Any medical or psychiatric condition that may interfere with the ability to comply
 with protocol treatment